Rhenman & Partners Asset Management Ab Bluebird Bio, Inc. Transaction History

Rhenman & Partners Asset Management Ab

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 19, 2021	SELL	$27.5 - $37.92 $2.96 Million - $4.09 Million	-107,797 Closed	0 $0
Q2 2020 Jul 16, 2020	BUY	$27.12 - $45.97 $1.11 Million - $1.88 Million	40,797 Added 60.89%	107,797 $6.58 Million
Q1 2020 Apr 16, 2020	BUY	$26.16 - $63.5 $261,600 - $635,000	10,000 Added 17.54%	67,000 $3.08 Million
Q4 2019 Jan 17, 2020	BUY	$46.96 - $61.67 $234,800 - $308,350	5,000 Added 9.62%	57,000 $5 Million
Q3 2019 Oct 16, 2019	SELL	$59.47 - $93.1 $1.07 Million - $1.68 Million	-18,000 Reduced 25.71%	52,000 $4.78 Million
Q2 2019 Jul 22, 2019	BUY	$75.84 - $105.21 $1.14 Million - $1.58 Million	15,000 Added 27.27%	70,000 $8.9 Million
Q1 2019 Apr 11, 2019	SELL	$64.44 - $104.11 $4.05 Million - $6.54 Million	-62,850 Reduced 53.33%	55,000 $8.65 Million
Q4 2018 Feb 05, 2019	BUY	$59.1 - $93.26 $6.96 Million - $11 Million	117,850 New	117,850 $11.7 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.